Ciprofloxacin Resistance and Gonorrhea Incidence Rates in 17 Cities, United States, 1991–2006

Chesson, Harrell W.; Kirkcaldy, Robert D.; Gift, Thomas L.; Owusu-Edusei, Kwame; Weinstock, Hillard

doi:10.3201/eid2004.131288

Cited by 18 publications

(18 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A reintroduction of the previous obligation to report all cases of gonorrhoea in Germany, currently under discussion, may answer this question in the future. An increasing gonorrhoea incidence, however, also might at least partially result from the previously discussed ciprofloxacin usage for empirical treatment of the infection in the presence of high resistance rates to this drug [ 29 ].…”

Section: Discussionmentioning

confidence: 99%

Antimicrobial resistance of Neisseria gonorrhoeae isolates in south-west Germany, 2004 to 2015: increasing minimal inhibitory concentrations of tetracycline but no resistance to third-generation cephalosporins

Regnath¹,

Mertes²,

Ignatius

2016

Eurosurveillance

View full text Add to dashboard Cite

Increasing antimicrobial resistance of Neisseria gonorrhoeae, particularly to third-generation cephalosporins, has been reported in many countries. We examined the susceptibility (determined by Etest and evaluated using the breakpoints of the European Committee on Antimicrobial Susceptibility Testing) of 434 N. gonorrhoeae isolates collected from 107 female and 327 male patients in Stuttgart, south-west Germany, between 2004 and 2015. During the study period, high proportions of isolates were resistant to ciprofloxacin (70.3%), tetracycline (48.4%; increasing from 27.5% in 2004/2005 to 57.7% in 2014/2015; p = 0.0002) and penicillin (25.6%). The proportion of isolates resistant to azithromycin was low (5.5%) but tended to increase (p = 0.08). No resistance and stable minimum inhibitory concentrations were found for cefixime, ceftriaxone, and spectinomycin. High-level resistance was found for ciprofloxacin (39.6%) and tetracycline (20.0%) but not for azithromycin; 16.3% of the isolates produced betalactamase. Thus, cephalosporins can still be used for the treatment of gonorrhoea in the study area. To avoid further increasing resistance to azithromycin, its usage should be limited to patients allergic to cephalosporins, or (in combination with cephalosporins) to patients for whom no susceptibility testing could be performed or those co-infected with chlamydiae.

show abstract

Section: Discussionmentioning

confidence: 99%

Antimicrobial resistance of Neisseria gonorrhoeae isolates in south-west Germany, 2004 to 2015: increasing minimal inhibitory concentrations of tetracycline but no resistance to third-generation cephalosporins

Regnath¹,

Mertes²,

Ignatius

2016

Eurosurveillance

View full text Add to dashboard Cite

show abstract

“…However, studies on outcome impacts due to gonococcal resistance are most needed to justify the investment to address the AMR in gonorrhea. However, evidence from studies on outcome impacts of gonococcal resistance [97,98] is relatively limited. Actually, investment to control of gonorrhea is disproportionately lower than many of other infectious diseases [99].…”

Section: Discussionmentioning

confidence: 99%

Outcome Impacts Due to Pathogen-Specific Antimicrobial Resistance: A Narrative Review of Published Literature

Jiang

Chen

2020

IJERPH

View full text Add to dashboard Cite

Antimicrobial resistance (AMR) has become a global threat to not only public health impacts but also clinical and economic outcomes. During the past decades, there have been many studies focusing on surveillance, mechanisms, and diagnostics of AMR in infectious diseases but the impacts on public health, clinical and economic outcomes due to emergence of these AMRs are rarely studied and reported. This review was aimed to summarize the findings from published studies to report the outcome impacts due to AMR of malaria, tuberculosis and HIV and briefly discuss the implications for application to other infectious diseases. PubMed/Medline and Google Scholar databases were used for search of empirical and peer-reviewed papers reporting public health, clinical and economic outcomes due to AMR of malaria, tuberculosis and HIV. Papers published through 1 December 2019 were included in this review. A total of 76 studies were included for this review, including 16, 49 and 11 on public health, clinical and economic outcomes, respectively. The synthesized data indicated that the emergence and spread of AMR of malaria, tuberculosis and HIV have resulted in adverse public health, clinical and economic outcomes. AMR of malaria, tuberculosis and HIV results in significant adverse impacts on public health, clinical and economic outcomes. Evidence from this review suggests the needs to consider the similar studies for other infectious diseases.

show abstract

“…The development of antibiotic resistance by pathogens to many antibiotics has increased concerns about the effective management of these diseases (Alirol et al 2017 ; Bala et al 2007 ; P. Health England 2013 ; Laibl et al 2005 ; Martin et al 2006 ; McCarthy 2007 ; MMWR 2006 ; Nys et al 2004 ; Wang et al 2005 ). For example, a positive correlation between ciprofloxacin resistance and gonorrhea incident rates has been reported in several countries leading to the drug being removed as the primary treatment option (Bala et al 2007 ; Chesson et al 2014 ; McCarthy 2007 ; MMWR 2006 ). Therefore, finding a way to optimally identify patients more likely to respond positively to an antibiotic regimen can represent a competitive advantage for disease management.…”

Section: Introductionmentioning

confidence: 99%

Liquid crystal delivery of ciprofloxacin to treat infections of the female reproductive tract

Pisano

Giustiniani

Francis

et al. 2019

Biomed Microdevices

View full text Add to dashboard Cite

Infections of the female reproductive tract are a major cause of morbidity and mortality in humans, requiring significant investment to sustain treatment and representing a major challenge to health. The increasing prevalence of bacterial resistance, and an almost complete absence of new antibiotic therapies for the past five decades, mean there is a desperate need for novel approaches to the treatment of bacterial infections. Within the present study, we demonstrate the effective ex vivo treatment of bacterial infection of the female reproductive tract using a controlled-release, liquid crystal-based platform. Liquid crystal encapsulation of ciprofloxacin significantly enhanced its bactericidal efficacy and reduced cell toxicity. Liquid crystal structures are low-cost, simple to manufacture and provide a sustained-release profile of encapsulated ciprofloxacin. Treatment of Escherichia coli infected reproductive tract epithelial cells and whole organ cultures with liquid crystal encapsulated ciprofloxacin proved to be an effective strategy for reducing bacterial load and reproductive tract inflammatory responses to infection. These data suggest that such an approach could provide an efficacious treatment modality for enhancing the effectiveness of current antibiotic therapies. Electronic supplementary material The online version of this article (10.1007/s10544-019-0385-x) contains supplementary material, which is available to authorized users.

show abstract

Ciprofloxacin Resistance and Gonorrhea Incidence Rates in 17 Cities, United States, 1991–2006

Cited by 18 publications

References 21 publications

Antimicrobial resistance of Neisseria gonorrhoeae isolates in south-west Germany, 2004 to 2015: increasing minimal inhibitory concentrations of tetracycline but no resistance to third-generation cephalosporins

Antimicrobial resistance of Neisseria gonorrhoeae isolates in south-west Germany, 2004 to 2015: increasing minimal inhibitory concentrations of tetracycline but no resistance to third-generation cephalosporins

Outcome Impacts Due to Pathogen-Specific Antimicrobial Resistance: A Narrative Review of Published Literature

Liquid crystal delivery of ciprofloxacin to treat infections of the female reproductive tract

Contact Info

Product

Resources

About